Back to News
Market Impact: 0.15
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Source: globenewswire.com
Healthcare & BiotechProduct Launches
An unspecified milestone is described as supporting broader U.S. adoption of Prosigna and expanding access for eligible patients with early-stage breast cancer. The article provides no details on the milestone, patient numbers, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- Tesla Showcases Long-Awaited Roadster With Aerial Tricks
- After years of U.S. export bans, China plans its own: 40 AI, chip and solar technologies could be restricted